NURIX THERAPEUTICS, INC.: income tax expense or benefit
Income tax expense or benefit for NURIX THERAPEUTICS, INC. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All NURIX THERAPEUTICS, INC. financial histories
What this measure means
Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.
Exact concept: us-gaap:IncomeTaxExpenseBenefit. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2018-12-01 to 2025-11-30. The SEC response was captured on 2026-09-20.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2024-12-01 | 2025-11-30 | 760,000 | USD | 2026-01-28 | 10-K · 0001549595-26-000016 |
| 2023-12-01 | 2024-11-30 | 270,000 | USD | 2026-01-28 | 10-K · 0001549595-26-000016 |
| 2022-12-01 | 2023-11-30 | 0 | USD | 2026-01-28 | 10-K · 0001549595-26-000016 |
| 2021-12-01 | 2022-11-30 | 0 | USD | 2025-01-28 | 10-K · 0001549595-25-000016 |
| 2020-12-01 | 2021-11-30 | 131,000 | USD | 2023-02-09 | 10-K · 0001549595-23-000021 |
| 2019-12-01 | 2020-11-30 | -20,535,000 | USD | 2022-01-28 | 10-K · 0001564590-22-003007 |
| 2018-12-01 | 2019-11-30 | 239,000 | USD | 2022-01-28 | 10-K · 0001564590-22-003007 |
Related financial histories
- NURIX THERAPEUTICS, INC.: total assets
- NURIX THERAPEUTICS, INC.: total liabilities
- NURIX THERAPEUTICS, INC.: stockholders equity
- NURIX THERAPEUTICS, INC.: cash and cash equivalents
- NURIX THERAPEUTICS, INC.: net income or loss
- NURIX THERAPEUTICS, INC.: operating cash flow
- NURIX THERAPEUTICS, INC.: capital expenditure payments
- NURIX THERAPEUTICS, INC.: revenue
- NURIX THERAPEUTICS, INC.: contract revenue excluding tax
- NURIX THERAPEUTICS, INC.: financing cash flow
- NURIX THERAPEUTICS, INC.: investing cash flow
- NURIX THERAPEUTICS, INC.: retained earnings or deficit
- NURIX THERAPEUTICS, INC.: basic weighted-average shares
- NURIX THERAPEUTICS, INC.: diluted weighted-average shares
- NURIX THERAPEUTICS, INC.: basic earnings per share
- NURIX THERAPEUTICS, INC.: diluted earnings per share
- NURIX THERAPEUTICS, INC.: net property, plant and equipment
- NURIX THERAPEUTICS, INC.: share-based compensation expense
- NURIX THERAPEUTICS, INC.: operating income or loss
- NURIX THERAPEUTICS, INC.: current assets
- NURIX THERAPEUTICS, INC.: current liabilities
- NURIX THERAPEUTICS, INC.: current accounts payable
- NURIX THERAPEUTICS, INC.: operating expenses
- NURIX THERAPEUTICS, INC.: research and development expense
Inspect the source
- Entity
- NURIX THERAPEUTICS, INC. / CIK 0001549595
- Captured
- 2026-09-20T09:18:28.636Z
- SEC response SHA-256
4cb046b66aed89a099e3971bfd46671a5b2c66ad3b5525d11ef8433039c0b364
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001549595.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))